ONCO stock forecast, quote, news & analysis
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology... Show more
Why Onconetix (ONCO) Is Down -45% in the Last 30 Days
Key Takeaways
- ONCO stock declined approximately -45% over the past 30 days amid high volatility, driven by weak financial results and Nasdaq compliance pressures.
- Over the past quarter, the stock fell around -55%, reflecting ongoing challenges in revenue growth and operational losses.
- Major factors include disappointing Q4 2025 earnings with minimal revenue, repeated reverse stock splits, and negative market sentiment in biotech sector.
- Recent 1-for-5 reverse split effective March 25, 2026, aimed at Nasdaq listing compliance but often signals distress to investors.
- Lack of positive catalysts like new partnerships or regulatory approvals contributed to sustained downward pressure.
Onconetix (ONCO) Company Overview and Market Position
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. Its core business model revolves around diagnostic tests such as Proclarix, a protein-based blood test for prostate cancer approved in the EU and licensed with LabCorp for U.S. marketing as a lab-developed test, and partnerships like PancreaSure with Immunovia AB. Operating in the competitive oncology diagnostics industry, Onconetix faces rivals with established portfolios and faces challenges from limited revenue generation and high R&D costs. These fundamentals, including persistent losses and low cash reserves, explain the stock's vulnerability to negative news and sector headwinds, contributing to recent price declines.
Onconetix (ONCO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ONCO stock has dropped approximately -45%, trading in a volatile, range-bound pattern between roughly $1.20 and $0.44 before recovering slightly to around $0.57 by late March. The movement was choppy, with sharp drops following earnings and news events, interspersed with brief rebounds on low volume.
In the past quarter, the stock declined about -55%, from levels near $1.43 in late December 2025 to current lows. Performance was trend-driven downward, punctuated by spikes around merger announcements that failed to sustain, amid overall biotech market trends and company-specific issues.
What Drove ONCO Stock Price in the Last 30 Days
The primary catalyst for the 30-day decline was Onconetix's Q4 2025 earnings release on March 13, 2026, reporting just $0.30 million in revenue and ongoing net losses exceeding $15 million for the year, highlighting stalled commercialization of Proclarix and lack of meaningful sales growth. This triggered immediate selling pressure.
The March 23 announcement of a 1-for-5 reverse stock split, effective March 25 to regain Nasdaq compliance, further eroded investor confidence, as such actions often precede delisting fears. High short interest and thin trading volume amplified volatility.
Biotech sector sentiment weakened due to macroeconomic factors like rising interest rates impacting funding, with no offsetting company news such as new deals or data readouts.
What Drove ONCO Stock Performance Over the Last Quarter
The quarter's downturn was fueled by broader operational struggles, including revenue contraction to $815,000 annually from prior periods, reflecting delays in U.S. Proclarix rollout and terminated merger talks with Ocuvex in September 2025. A $12.9 million financing via preferred stock provided short-term liquidity but diluted common shareholders.
Repeated Nasdaq deficiency notices and prior reverse splits (1-for-85 in June 2025) signaled chronic compliance issues, deterring institutional investors. Oncology sector trends, including regulatory hurdles and competition in diagnostics, compounded the pressure.
Macro conditions like elevated rates reduced biotech M&A activity, while institutional selling on poor fundamentals had the strongest cumulative impact, leading to the sustained decline.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from hundreds available, scanning thousands of tickers across various markets. These curated bots employ diverse strategies—such as trend-following, mean reversion, or momentum plays—across short-term intraday to long-term swings, with performance metrics like win rate, profit factor, and Sharpe ratio prominently displayed. Updated in real-time, the section highlights bots with consistent outperformance amid current market trends, helping traders identify tools aligned with their risk tolerance and goals. Explore Trending AI Robots to integrate advanced automation into your stock analysis today.
ONCO Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming quarterly earnings for progress on Proclarix U.S. launch and revenue traction. Nasdaq compliance post-reverse split remains critical, with potential delisting risks if bid price stays below $1.00.
Strategic developments like the proposed Realbotix acquisition into AI robotics could shift focus, alongside any new partnerships or clinical data for oncology tests. Industry trends in diagnostics demand and biotech funding environment will influence sentiment.
Risks include further dilution from financings, regulatory delays, and competition; catalysts may arise from successful commercialization or M&A activity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
ONCO in -12.60% downward trend, declining for three consecutive days on June 18, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONCO declined for three days, in of 366 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for ONCO entered a downward trend on June 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ONCO advanced for three days, in of 153 cases, the price rose further within the following month. The odds of a continued upward trend are .
ONCO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.298) is normal, around the industry mean (20.966). P/E Ratio (0.002) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ONCO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.043) is also within normal values, averaging (367.026).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ONCO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology